Emerging role of metagenomic next‐generation sequencing in infectious disease diagnostics: Clinical integration and future directions
mLife · 2026-04 · 5 (2) · 148-163
DOI: 10.1002/mlf2.70078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift mLife, online erschienen am 30.04.2026. Verfasst von Tingting Fang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Zhongshan Hospital Fudan University Shanghai China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Infectious disease diagnostics has been transformed by metagenomic next‐generation sequencing (mNGS), an unbiased approach that detects bacteria, viruses, fungi, and parasites in a single assay. By sequencing all nucleic acids in a sample, mNGS overcomes the narrow detection scope and slow turnaround of conventional tests, substantially improving pathogen detection. In conditions such as meningitis/encephalitis, sepsis, and pneumonia, mNGS frequently identifies etiologies missed by routine diagnostic tests, thereby facilitating earlier pathogen‐directed therapy and, in selected settings, improving clinical management and outcomes. This approach is particularly valuable for immunocompromised, pediatric, and intensive care unit (ICU) patients with atypical infections. Currently, clinical mNGS workflows primarily rely on short‐read sequencing platforms (e.g., Illumina), whereas long‐read platforms (e.g., Nanopore, PacBio) offer advantages for rapid or high‐resolution applications. Optimized bioinformatics and stringent quality control are essential for reliable results. Beyond clinical diagnostics, mNGS provides valuable genetic data on antimicrobial resistance (AMR) and pathogen phylogeny, supporting public health and outbreak surveillance (e.g., wastewater monitoring and variant tracking). Current challenges include distinguishing colonization from infection, interpreting sequencing data quantitatively, and reducing cost and turnaround time. Looking ahead, emerging strategies such as targeted panels, rapid automated workflows, and host‑response integration are expected to further shorten time‑to‑result and improve diagnostic specificity. Parallel progress in ethical and regulatory frameworks remains essential to ensure responsible implementation. To support clinical adoption, a standardized framework for clinical interpretation of mNGS results, together with associated training, has been developed and implemented. Overall, mNGS is likely to become an increasingly important component of infectious disease diagnostics, with ongoing innovations expected to broaden its clinical and epidemiological impact.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, Zhongshan Hospital Fudan University Shanghai China.
ORCID-Profile: Bijie Hu
Zitieren
APA
Fang, T., Yuan, F., Chen, Y., Li, N., Zhang, Y., Liu, H., Liu, X., Miao, Q., & Hu, B. (2026). Emerging role of metagenomic next‐generation sequencing in infectious disease diagnostics: Clinical integration and future directions. mLife, 5(2), 148-163. https://doi.org/10.1002/mlf2.70078
Vancouver
Fang T, Yuan F, Chen Y, Li N, Zhang Y, Liu H, et al. Emerging role of metagenomic next‐generation sequencing in infectious disease diagnostics: Clinical integration and future directions. mLife. 2026;5(2):148-163. doi:10.1002/mlf2.70078
BibTeX
@article{Fang2026,
author = {Fang, Tingting and Yuan, Feifei and Chen, Yu and Li, Na and Zhang, Yao and Liu, Haixia and Liu, Xingchen and Miao, Qing and Hu, Bijie},
title = {Emerging role of metagenomic next‐generation sequencing in infectious disease diagnostics: Clinical integration and future directions},
journal = {mLife},
year = {2026},
volume = {5},
number = {2},
pages = {148--163},
doi = {10.1002/mlf2.70078}
}
EUVIMED